The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

On April 2, 2025, Cingulate completed its Pre-NDA meeting with the FDA to discuss the submission of an NDA for CTx-1301, its ...

Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.

Company announcement - No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabi ...

Cadence has announced a new AI supercomputer featuring Nvidia RTX Pro 6000 Blackwell Server Edition GPUs, HGX B200 systems, ...